1. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab
- Author
-
Timothy F. Cloughesy, Benjamin M. Ellingson, Albert Lai, Shadi Lalezari, Paul S. Mischel, Phioanh L. Nghiemphu, Whitney B. Pope, Kourosh Motevalibashinaeini, and Taryar Zaw
- Subjects
Vascular Endothelial Growth Factor A ,Diagnostic Imaging ,Cancer Research ,Relaxometry ,Bevacizumab ,Image Processing ,DQT2 ,Oncology and Carcinogenesis ,Brain Edema ,Angiogenesis Inhibitors ,Kaplan-Meier Estimate ,Antibodies, Monoclonal, Humanized ,GBM ,Brain mapping ,Disease-Free Survival ,Antibodies ,Computer-Assisted ,Magnetic resonance imaging ,Text mining ,Monoclonal ,Image Processing, Computer-Assisted ,Medical imaging ,medicine ,Humans ,Oncology & Carcinogenesis ,Humanized ,Survival analysis ,Retrospective Studies ,Brain Mapping ,medicine.diagnostic_test ,Brain Neoplasms ,business.industry ,Neurosciences ,Subtraction ,Magnetic Resonance Imaging ,Survival Analysis ,Neurology ,Oncology ,Disease Progression ,Angiogenesis ,Neurology (clinical) ,Glioblastoma ,Nuclear medicine ,business ,MRI ,medicine.drug - Abstract
The purpose of the current study was to quantify the reduction in T2 signal abnormality accompanying administration of the anti-angiogenic drug bevacizumab in recurrent glioblastoma (GBM) patients using a voxel-wise differential quantitative T2 (DQT2) mapping technique. Twenty-six patients with recurrent GBM treated with bevacizumab were scanned before and 4-6 weeks after treatment on a 1.5T clinical MR scanner. Quantitative T2 maps were created from proton density and T2-weighted images acquired using a standard multi-echo fast-spin echo sequence. T2 maps after treatment were co-registered with T2 maps prior to treatment in the same patient, and then voxel-wise subtraction was performed to create DQT2 maps for each patient. Results suggest DQT2 maps allow visualization and quantification of voxel-wise T2 changes resulting from anti-VEGF therapy. Results demonstrated a significant decrease in T2 within pre-treatment T2 abnormal regions (mean reduction = 49.4 ms at 1.5T) following anti-VEGF treatment (Wilcoxon signed rank test, P < 0.0001). An elevated residual, post-treatment, median T2 was predictive of both progression-free (Log-rank, P = 0.0074) and overall survival (Log-rank, P = 0.0393). © 2011 Springer Science+Business Media, LLC.
- Published
- 2011
- Full Text
- View/download PDF